2. Search Result
Search Result
Results for "

HT-1080+cells

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100579
    Ferrostatin-1
    Maximum Cited Publications
    1548 Publications Verification

    Fer-1

    		 Ferroptosis Fungal Cancer
    Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .
    Ferrostatin-1
  • HY-50908
    Ridaforolimus
    10+ Cited Publications

    MK-8669; Deforolimus; AP23573

    		 mTOR Autophagy Bacterial Cancer
    Ridaforolimus (MK-8669) is a potent and selective mTOR inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells .
    Ridaforolimus
  • HY-145669
    DIF-3
    5+ Cited Publications

    		 Wnt CDK GSK-3 Infection Cancer
    DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo .
    DIF-3
  • HY-153698
    CC-3060

    		Molecular Glues Ligands for E3 Ligase Cancer
    CC-3060 is a molecular glue modulator targeting Cereblon (CRBN) E3 ubiquitin ligase and ZBTB16 degrader with a DC50 of 0.47 nM in HT-1080 cells. CC-3060 engages structural degrons on ZBTB16’s ZnF1 or ZnF3 domains for fusion protein substrates. CC-3060 can be used for the research of acute promyelocytic leukemia .
    CC-3060
  • HY-149236
    PROTAC GPX4 degrader-1

    		PROTACs Glutathione Peroxidase Ferroptosis Cancer
    PROTAC GPX4 degrader-1 (DC-2) is a PROTAC-based GPX4 degrader, with a DC50 of 0.03 μM in HT1080 cells .
    PROTAC GPX4 degrader-1
  • HY-111844
    PROTAC RAR Degrader-1

    		PROTACs SNIPERs RAR/RXR Neurological Disease Metabolic Disease Cancer
    PROTAC RAR degrader-1 (Compound 9) is a potent and selective RAR PROTAC Degrader consisting of apoptotic protein inhibitors (IAPs) ligands. IAPs-based degraders are also known as SNIPERs. PROTAC RAR Degrader-1 reduces RARα levels in HT1080 cells in a concentration-dependent manner but is blocked by the proteasome inhibitor MG132 (HY-13259). PROTAC RAR Degrader-1 can be used in the study of nuclear receptor-related diseases. (Pink: RAR ligand 1 (HY-111843); Black: Linker (HY-140189); Blue: IAPs Ligand (HY-B0134)) .
    PROTAC RAR Degrader-1
  • HY-169133
    GDCNF-11

    		PROTACs Glutathione Peroxidase Ferroptosis Cancer
    GDCNF-11 is a HIM-PROTAC GPX4 degrader based on the chaperone protein HSP90. GDCNF-11 promotes the ubiquitination and degradation of GPX4 through the HSP 90 chaperone complex, reduces endogenous GPX4 expression to induce ferroptosis in HT-1080 cells, and the DC50 value is 0.08 μM (Pink: Target protein ligand (HY-153748); Blue: HSP90 ligand (HY-10212); Black: Linker (HY-W169526)) .
    GDCNF-11
  • HY-173029
    UAMC-4821

    		Ferroptosis Cancer
    UAMC-4821 is an inhibitor for ferroptosis with an IC50 of 5.2 nM. UAMC-4821 scavenges free radicals, blocks the lipid peroxidation, inhibits ML162 (HY-100002)-induced ferroptosis, and exhibits protective effect in HT-1080 cell. UAMC-4821 exhibits good pharmacokinetics characteristics in mouse with an oral bioavailability of 63%. UAMC-4821 can cross blood-brain barrier .
    UAMC-4821
  • HY-149670
    Ferroptosis-IN-3

    		Ferroptosis Inflammation/Immunology
    Ferroptosis-IN-3 (Compound 25) is a ferroptosis inhibitor. Ferroptosis-IN-3 inhibits RSL3-induced ferroptosis (EC50: 8.6?nM in HT-1080?cells). Ferroptosis-IN-3 scavenges DPPH and ABTS radicals (EC50: 3.94?and 6.3 μM respectively). Ferroptosis-IN-3 decreases lipid peroxidation .
    Ferroptosis-IN-3
  • HY-159771
    FAP6-19

    		FAP Cancer
    FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
    FAP6-19
  • HY-175041
    GPX4-IN-18

    		Glutathione Peroxidase Reactive Oxygen Species (ROS) Cannabinoid Receptor Ferroptosis Cancer
    GPX4-IN-18 (Compound 17) is a ferrocene-containing inhibitor of glutathione peroxidase 4 (GPX4). GPX4-IN-18 is also an inducer of ferroptosis. GPX4-IN-18 can increase the production of ROS and malondialdehyde (MDA) levels in OS-RC-2 clear cell renal cell carcinoma cells. GPX4-IN-18 induces ferroptosis in HT-1080 cells with IC50s of 0.007 μM (absence of ferrostatin-1) and 1.486 μM (presence of ferrostatin-1). GPX4-IN-18 reduces in vivo tumor volume and intratumoral GPX4 levels in OS-RC-2 xenograft murine model .
    GPX4-IN-18
  • HY-175213
    Mutant IDH1-IN-7

    		Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-7 is a highly selective Isocitrate Dehydrogenase 1 (IDH1) R132H (IC50 = 0.26 μM, Kd = 2.1 μM)/R132C (IC50 = 1.1 μM) inhibitor. Mutant IDH1-IN-7 has no inhibitory effect on wild-type IDH1, IDH2-wt, and IDH2 R140Q. Mutant IDH1-IN-7 inhibits 2-Hydroxyglutarate (2-HG) production in U87-MG R132H cells (EC50 = 0.55 μM). Mutant IDH1-IN-7 exhibits moderate antiproliferative effects on U87-MG R132H and HT-1080 cells .
    Mutant IDH1-IN-7
  • HY-149359
    IHMT-IDH1-053

    		Isocitrate Dehydrogenase (IDH) Cancer
    IHMT-IDH1-053 (compound 16) is a highly selectivity and irreversible IDH1-mutant inhibitor with an IC50 of 4.7 nM for IDH1 R132H. IHMT-IDH1-053 displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. IHMT-IDH1-053 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC50=28 nM). IHMT-IDH1-053 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. IHMT-IDH1-053 inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants .
    IHMT-IDH1-053
  • HY-161930
    PROTAC GPX4 degrader-3

    		PROTACs Ferroptosis Cancer
    PROTAC GPX4 degrader-3 is a potent PROTAC GPX4 degrader with a DC50 (24h) of 0.019 μM and an IC50 of 0.024 μM in HT1080 cell .
    PROTAC GPX4 degrader-3
  • HY-162718
    GPX4-IN-12

    		Ferroptosis Cancer
    GPX4-IN-12 (compound I22) is a non-covalent GPX4 inhibitor. GPX4-IN-12 induces ferroptosis and inhibits cell growth of HT1080 cells .
    GPX4-IN-12
  • HY-162716
    GPX4-IN-10

    		Ferroptosis Cancer
    GPX4-IN-10 (compound I20) is a non-covalent GPX4 inhibitor. GPX4-IN-10 induces ferroptosis and inhibits cell growth of HT1080 cells .
    GPX4-IN-10
  • HY-161948
    Ferroptosis inducer-4

    		Ferroptosis Cancer
    Ferroptosis inducer-4 (Compound 5) is a ferroptosis (Ferroptosis) inducer with a structure featuring terminal double bonds introduced at the sn-2 position of phospholipids. Ferroptosis inducer-4 exhibits significant cytotoxicity towards HT-1080 cells, with an IC50 of 18 μM. This cytotoxic mechanism involves the generation of lipid peroxides and oxidative damage to the cell membrane triggered by the terminal double bonds. Ferroptosis inducer-4 can be used for research on ferroptosis regulation .
    Ferroptosis inducer-4
  • HY-170959
    NYY-6a

    		Ferroptosis Neurological Disease Metabolic Disease
    NYY-6a is a Ferroptosis inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC50s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .
    NYY-6a
  • HY-143234
    mIDH1-IN-1

    		Isocitrate Dehydrogenase (IDH) Cancer
    mIDH1-IN-1 (compound 43) is a potent and selective mIDH1 (mutant isocitrate dehydrogenases 1) inhibitor, with an IC50 of 961.5 nM. mIDH1-IN-1 potently inhibits intracellular 2-HG (2-hydroxyglutarate) production in HT1080 cells, with an EC50 of 208.6 ± 8.0 nM. mIDH1-IN-1 shows a significant anti-proliferation activity on IDH1 mutant-U-87 cells, with an IC50 of 41.8 nM. mIDH1-IN-1 is an antitumor agent, and can be used for IDH1 mutated solid tumors research .
    mIDH1-IN-1
  • HY-N0998
    1,7-Bis(4-hydroxyphenyl)-hepta-4E,6E-dien-3-one

    		Melanocortin Receptor Cancer
    1,7-Bis(4-hydroxyphenyl)-hepta-4E,6E-dien-3-one (compound 6) shows antiproliferative activity with ED50s of 57.7, 78.8 μM for 26-L5 and HT-1080 cells, respectively. 1,7-Bis(4-hydroxyphenyl)-hepta-4E,6E-dien-3-one inhibits melanogenesis in B16 melanoma 4A5 cells. 1,7-Bis(4-hydroxyphenyl)-hepta-4E,6E-dien-3-one has the potential for the research of skin disorders .
    1,7-Bis(4-hydroxyphenyl)-hepta-4E,6E-dien-3-one
  • HY-161972
    ZX782

    		HyT Ferroptosis Glutathione Peroxidase Cancer
    ZX782 is a HyT GPX4 degrader and a ferroptosis inducer, which induces GPX4 degradation and significantly increases lipid ROS accumulation in HT1080 cells. ZX782 can be used to treat AD by reducing the size and/or number of brain amyloid plaques and by inhibiting the spread of IL-1beta-positive microglial-like cells around amyloid plaques. ZX782 is labeled with hydrophobic benzyl alcohol (HBA) and appears bright blue under acidic conditions, which can be used for quantitative determination . ZX782 is composed of target protein ligand (red part) ML-210 (HY-100003), PROTAC linker (black part) Bromo-PEG2-CH2-Boc (HY-141371) and Hty molecule (blue part) Adamantan-1-ylmethanamine (HY-W037848). The conjugate consisting of Hyt and linker parts is Adamantan-C-amide-PEG2-C-Br (HY-161974), and the activity control of the target protein ligand is Hydroxyl-ML-210 (HY-161973).
    ZX782
  • HY-120015
    BE-16627B

    		MMP Cancer
    BE-16627B is a metalloproteinase inhibitor. BE-16627B can be isolated from microbial cultures. BE-16627B can inhibit metalloproteinases in enzyme assays. BE-16627B reduces the number and size of HT1080 cell nodules on lung surface in mouse models. BE-16627B inhibits growth of HT1080 cells in mice. BE-16627B can be studied in anti-cancer research .
    BE-16627B
  • HY-181598
    GPX4 degrader-1

    		HyT Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS) Cancer
    GPX4 degrader-1 (Compound RS-1) is a hydrophobic tagging (HyT)-mediated GPX4 degrader (DC50: 8.9 nM in HT1080 cells) GPX4 degrader-1 induces GPX4 degradation. GPX4 degrader-1 induces Ferroptosis. GPX4 degrader-1 increases lipid ROS. GPX4 degrader-1 demonstrates potent antitumor efficacy in a murine mammary carcinoma model .
    GPX4 degrader-1
  • HY-100579R
    Ferrostatin-1 (Standard)

    Fer-1 (Standard)

    		 Ferroptosis Reference Standards Fungal Cancer
    Ferrostatin-1 (Standard) is the analytical standard of Ferrostatin-1 (HY-100579). This product is intended for research and analytical applications. Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .
    Ferrostatin-1 (Standard)
  • HY-115465
    Rev1-CT/RIR PPI-IN-1

    		DNA/RNA Synthesis Cancer
    Rev1-CT/RIR PPI-IN-1 (Compound 1) is a thiophene-based compound. Rev1-CT/RIR PPI-IN-1 can specifically disrupt the protein-protein interaction between Rev1-CT and RIR, with an IC50 value of 2.5 µM. Rev1-CT/RIR PPI-IN-1 can enhance chemosensitivity and reduce the mutation rate in Cisplatin (HY-17394)-sensitive HT-1080 cells. Rev1-CT/RIR PPI-IN-1 can be used for tumor research .
    Rev1-CT/RIR PPI-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: